Until recently, biotech companies tended to be founded with a focus on a single technology or biological pathway.… Over the past five years, however, an innovative business model has emerged for biotech. In it, a portfolio manager controls a set of companies spanning multiple technologies and disease areas. Instead of focusing on a single technology or in the traditional way, the portfolio manager uses a distinctive form of expertise—such as in fundraising, investment, venture creation, R&D, manufacturing, commercial management, leadership, and broad credibility—to start a suite of subsidiaries, each dedicated to an individual drug program.
In the latest article by Mckinsey & Company A new portfolio model for biotech, the new model is analyzed in terms of its opportunities for the biopharmaceutical industry.
